73 results about "Amino acid binding" patented technology

Various biodegradable polyglutamate conjugates comprising recurring units of the general formulae (I), (II), (III), (IV), (V), and / or (VI) are prepared. The polymers are conjugated with a plurality of drugs. Such polymer conjugates are useful for variety of drug, targeting, stabilizing and / or imaging agent delivery applications.

The invention relates to a method for the in vitro diagnosis of Alzheimer's disease using a monoclonal antibody. Said antibody can bind at least to amino acids 12-16 of the β-amyloid peptide, specifically detecting the neuritic plaques which are characteristic of Alzheimer's disease, without detecting diffuse plaques which are not defining characteristics of the disease. Within the neuritic plaques, the monoclonal antibody can detect a different sub-group in the composition of the different deposited isoforms of the β-amyloid peptide, which is associated with the disease progression stage. In addition, the antibody can bind to isoforms of the β-amyloid peptide in biological fluids such as urine. As a result, the inventive monoclonal antibody, the cell lines that produce said antibody and compositions containing same can be used in the in vitro diagnosis of Alzheimer's disease and in determining the disease progression stage.

Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) ligand (PD-L1) and inhibit PD-L1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD-L1-mediated functions.

The invention discloses a method for preparing calcium amino acid, including the preparation of a culture liquid which consists of fish bone powder and enzymolysis protein liquid and the inoculation of lactobacillus acidophilus and streptococcus thermophilus in the culture liquid, then a fermentation liquid which consists of the fish bone powder and the enzymolysis protein liquid is prepared; the mixture of the lactobacillus acidophilus culture liquid and the streptococcus thermophilus culture liquid are inoculated into the fermentation liquid for fermentation, and the fermentation liquid is treated with centrifugation to obtain a yellow calcium amino acid clear liquid. The invention takes tilapia processing offcut-fish bone as main raw material by the combination of the enzymolysis and microbial fermentation; the enzymolysis protein liquid which is prepared by enzymolysis is taken as a protein source, the calcium in the fish bone is freed to be combined with the amino acid in the enzymolysis protein liquid to form the ionic-state calcium amino acid by the fermentation of the lactobacillus acidophilus and the streptococcus thermophilus. The invention can not only high-value utilize the tilapia processing offcut, but also can improve the processing utilization ratio of the tilapia.

A liposome composition for treating a bacterial infection is described. The composition includes liposomes having a surface coating of hydrophilic polymer chains and an entrapped drug-conjugate composed of a quinolone compound conjugated to an amino acid.

The presently described technology provides a novel class of prodrugs of quetiapine that can be synthesized by chemically conjugating amino acids to quetiapine. The present technology also provides methods of treating patients, pharmaceutical compositions and methods of synthesizing conjugates of the present technology.

The present invention relates to a method of modulating a chromatin binding protein or complex which binds to a functional group on an amino acid of a histone. This method involves phosphorylating or dephosphorylating a serine or threonine on the histone proximate to the amino acid under conditions effective to modulate the chromatin binding protein or complex. This method is particularly useful in treating or preventing cancer in a subject. In addition, the histone comprising a serine or threonine proximate to an amino acid capable of binding to a functional group can be used to screen for compounds which prevent or treat cancer. Also disclosed is an antibody or binding portion thereof raised against a binary switch on a histone comprising a phosphorylated serine or threonine proximate to an amino acid bound to a functional group and its use in detecting a condition mediated by that switch.

The invention relates to a soil restoration agent containing a biological surface active material. The soil restoration agent is obtained by combining bio-surfactant rhamnolipid, sucrose ester, humic acid and amino acids and adding Chinese herbal medicinal ingredients such as indigowoad root and herba taraxaci which have a sterilization function, the soil restoration agent has functions of improving soil granular structure and soil property, enhancing soil fertility, restraining soil-borne diseases and improving crop quality, pesticide residues and passivated heavy metals can also be effectively reduced, all components of the soil restoration agent are completely biodegradable, and the soil restoration agent does not lead to secondary pollution to the environment and belongs to green environment-friendly products.

The invention discloses a method for producing hemepeptide by using red blood cells of animal blood as raw materials. The method comprises the following steps of: adding water into the red blood cells of the animal blood, stirring for wall breakage, heating, performing thermal denaturation, adjusting the pH of the obtained mixture to be between 7.5 and 9.0 at the temperature of between 40 and 60 DEG C, adding special enzyme 1122 for blood cell hydrolysis in a ratio of 1,000 to 2,500U / (g protein), performing enzymolysis for 4 to 8 hours with stirring, inactivating the enzyme, filtering, concentrating the filtrate, performing spray drying, and thus obtaining the hemepeptide. According to the method, the red blood cells are subjected to wall breakage and thermal denaturation, so that the double-spiral structure of the red blood cell protein becomes loose, the special enzyme 1122 for blood cell hydrolysis enters the amino acid binding sites in the red blood cell protein more easily to perform enzymolysis, and the enzymolysis rate is improved; and the adopted special enzyme 1122 for blood cell hydrolysis can be used for simultaneous enzymolysis of multiple amino acid binding sites of the red blood cell protein, so that the enzymolysis efficiency and the yield are further improved, and the yield of the whole hydrolysis process reaches over 78 percent.

The invention relates to a preparation method of hypoglycemic health food rich in a plurality of trace elements combining with glucose tolerance factors, comprising the following steps: adding a certain amount of grains in a square container, respectively dissolving salts of chromium, magnesium, zinc, manganese, copper, nickel, cobalt, selenium, vanadium, and molybdenum by using acid water and then pouring into the square container, rotating the container for 8-12h until the acid water is completely absorbed by the grains; drying the grains, and then curing to obtain the hypoglycemic health food. According to the invention, the health food is rich in a plurality of trace elements combining with the glucose tolerance factors, wherein the trace elements combine with amino acid to form amino acid salts which can easily be absorbed by human body; the product meets the limitation requirements of each trace element in food hygienic standards of China, regular consumption of the product by the diabetics can keep the metabolic balance of the trace elements in the body, can prevent and correct the metabolic disorders of inorganic salts and the trace elements, and has good effects of preventing and treating diabetes and health protection.

The invention is a production process of a novel resin, which is characterized in that it is prepared through condensation reaction of acrolein and vinyl ethyl ether. The new resin is composed of a high polymer of heteropolyene ether aldehyde and a certain amount of EOHP. It is a kind of pyranyl ether antibacterial body. They are the only ones in the world that only contain carbon (C) hydrogen (H) oxygen (O ) three-element and halogen-free antibacterial functional group, which can be biodegraded in the environment. When the surface of the new resin is in contact with the air, microorganisms adhere and gather to form a so-called biofilm. The antibacterial alkyl ether on the resin layer can penetrate the 1.8mm biofilm cell wall within 20 minutes and combine with amino acids, making it impossible for microorganisms to absorb nutrients and eliminate waste. The novel resin obtained by the production process of the invention has long-acting and durable antibacterial function. The antibacterial group of the new resin has a very fast bactericidal effect, and the bactericidal rate can reach more than 99% in an average of 2-5 hours.

The invention relates to an amino acid bound with polyethylene glycol with the following general structure: R-PEG-CO-X-amino acid or R-PEG-X-amino acid; wherein, PEG represents for polyethylene glycol chain; R represents for a hydroxyl group or an oxyl; the oxyl can be chosen from the C1 to C12 alkoxy, cycloalkoxy or aralkoxy; wherein, X represents for the heteroatom with active hydrogen removed except Alpha-carboxyl and Alpha-amino group in amino acid. Utilizing the amino acid bound with polyethylene glycol to synthesis polypeptide, the polypeptide is made from polypeptide positioned on specific position, not only improving the pharmacokinetics, but also having no effect of original treatment. The invention discloses the production method for the amino acid bound with polyethylene glycol.

An improved anticoagulant is based on a higher level of citric acid than is usual (at least about 0.2% weight by volume). The higher citrate is combined with an amino acid as a counterion. The amino acid prevents cellular damage often caused by elevated citrate levels. The amino acid citrate mixture also serves to preserve platelet concentrates and platelet rich plasma during room incubation. Not only does the amino acid citrate combination enhance platelet integrity, it completely inhibits the growth of bacteria such as Staphylococcus epidermidis. Collecting blood of plasma into such higher levels of citrate prevents activation of blood proteins so that fractions made from the blood or plasma have superior characteristics.

The subject matter of the invention is an electroconducting nanowire, comprising an amyloid fibre which results from the self-assembling of peptides comprising a prion domain or a derivative of this domain and which is functionalized by electron transporting peptides, each comprising amino acids bound to one or more atoms of iron.Its subject matter is also a method of manufacturing this nanowire as well as the uses of said nanowire.Uses: manufacture of sensors for the detection of chemical or biological species, of nano-batteries, of radio-identification systems, of molecular memory systems, etc.

This invention relates to a peptide nucleic acid (PNA) oligomer which is conjugated with one or more linear-type amino acid containing a plurality of alkyleneglycols and to a synthesis method thereof. In addition, this invention related to a linear amino acid spacer in a device for detection for detecting a target gene using the PNA oligomers which is fixed on a surface of a functionalized solid support. The linear amino acid spacer contains a plurality of alkyleneglycols and maintains enough space between the solid support and PNA oligomer in the device in order to prevent the interference of the interaction between the PNA oligomer and a target gene. Furthermore, this invention relates to a PNA array, a PNA chip and a gene diagnosis kit whereof sensitivity and specificity are improved by being manufactured with the PNA conjugated with the amino acid spacer.

The invention discloses a preparation method of an organic fertilizer rich in mineral elements. The preparation method comprises the following steps: S1, crushing coal gangue; S2, molding; S3, thermalactivation; S4, quenching; S5, drying; S6, crushing, and S7, mixing the raw materials, and mixing the coal gangue powder, the willow bark, the straw powder, the livestock manure, the mixed strain powder and the amino acid in a stirrer to obtain a mixture; S8; dispersing: dispersing the mixture obtained in the S7, exposing the dispersed mixture to the sun for 3-5 hours, and ventilating and airingto obtain the organic fertilizer. According to the invention, trace elements in soil are supplemented, and soil activity, water retention and air permeability are improved; in the activation process of the coal gangue, micropores and mesopores are formed, a carrier is provided for strains in soil, and propagation of microorganisms is facilitated; the heavy metals in the soil can be removed, and after the amino acids are decomposed, the heavy metals combined with the amino acids can be solidified in micropores and mesopores of the coal gangue.

The invention belongs to the technical field of medicine, and discloses a decitabine 5'-O-amino-acid ester prodrug for treating myelodysplastic syndrome and a preparation method thereof. The decitabine is subjected to purposeful structure modification, so that the decitabine is combined with different amino acids, thereby designing and synthesizing the compound decitabine 5'-O-amino-acid ester prodrug disclosed as (I). In (I), R is an amino acid, preferably L-valine, D-valine, L-isoleucine, L-phenylalanine or L-tryptophane. Compared with oral decitabine, the invention obviously enhances the bioavailability of the prodrug, and is hopeful to develop a carrier prodrug with more definite curative effect for treating myelodysplastic syndrome.

The invention relates to a conjugate comprising (a) an amatoxin comprising (i) an amino acid 4 with a 6′-deoxy position; and (ii) an amino acid 8 with an S-deoxy position; (b) a BCMA-binding moiety comprising (i) the variable domains of humanized antibody J22.9-ISY, and (ii) a heavy chain constant region comprising a D265C mutation; and (c) a protease-cleavable linker linking said amatoxin and said target-binding moiety. The invention furthermore relates to a pharmaceutical composition comprising such conjugate, particularly for use in the treatment of multiple myeloma.

The invention belongs to the technical field of medicaments, and discloses a substituted L-amino acid ester pro-medicament of an anti-AIDS medicament-didanosine and a preparation method thereof. The invention performs purposeful structural modification on the didanosine, ensures that the didanosine is combined with different amino acids, and designs and synthesizes a compound of a (I) structure, namely a didanosine pro-medicament. Compared with oral didanosine, the bioavailability of the compound is obviously improved and is equivalent to that of intravenously administrable didanosine. The pro-medicament and the preparation method are expected to develop a carrier pro-medicament with better therapeutic effect for treating AIDS. In the (I), R is L-type amino acid residue, and the L-type amino acid residue is preferably selected from L-valine, L-isoleucine, L-phenylalanine, L-proline and L-tryptophan.

The invention discloses porcine transmissible gastroenteritis virus (TGEV) fusion protein as well as a preparation method and application thereof. The fusion protein S1-TAT provided by the invention comprises a sequence of a main antigenic site of the S protein of the TGEV and 11 core amino acids bound to a basic amino acid-rich region of the TAT protein transduction peptide at the C-terminal of the sequence. Mice are immunized with the fusion protein S1-TAT by means of intraperitoneal injection or intragastric administration, so that the production of specific serum IgG antibodies and sIgA mucosal antibodies can be effectively induced, and good immunogenicity is achieved; TAT can carry S1 protein which is expressed in fusion with the TAT, and passes through intestinal wall cells; the fusion protein S1-TAT has no effect on the growth of the mice. Therefore, the TGEVS1 protein and the TAT are expressed in a fusion way, so that a new method is provided for prevention of TGEV infection, and a foundation is also laid for the development of a novel vaccine for the TGEV.

The present invention relates to a production method for a health care food, wherein the health care food is rich in multiple trace elements so as to promote growth and development. The production method comprises: filling 10 kg of grains into a square container, respectively weighing chromium chloride, sodium selenite, ferric chloride, potassium iodide, zinc chloride, manganese chloride, copper sulfate, sodium molybdate, stannous chloride, sodium fluoride and sodium tetraborate, mixing the salts, adding water to dilute to obtain a mixed salt solution, and carrying out drying crushing after the salt solution is completely absorbed by the grains to obtain the health care food. The health care food is rich in multiple trace elements required by people, wherein the trace elements and amino acids are combined to form multiple amino acid salts, and the amino acid salts are easily absorbed by human bodies so as to maintain balance of multiple trace elements in the human body, improve resistance of young children, reduce generation of a variety of diseases, promote growth and development, and provide a good health care function.

The invention discloses a conjugate, which includes a mutant syphilis detection antigen and a marker. Through gene mutation of the syphilis detection antigen, one or more lysine in the middle of the syphilis detection antigen can be mutated. The lysine easy to combine with the marker in the middle of the syphilis detection antigen turns into other amino acids, so that the marker is marked at a lysine site at the N terminal or C terminal of the mutant syphilis detection antigen and does not combine with the middle part amino acid, thus avoiding wrapping of the antigen active site by the marker. Compared with traditional reagents, the antigen active site of the conjugate is not wrapped by the marker, the antigenic activity decrease caused by combination of antigen determinants and the marker can be avoided, thereby not affecting the antigen activity. The conjugate can improve the detection sensitivity and specificity when used for syphilis detection, and can avoid the prozone phenomenon. The invention also discloses the preparation method and application of the conjugate.

An organogallium enriched bean-sprout for preventing asteoporosis, hipertension, coronary heart disease and arteriosclerosis is prepared through immersing bean in the solution of gallium and sprouting and growing in it.

The invention discloses a preparation method of a nitrogen-doped bismuthyl carbonate catalyst. The preparation method comprises the following steps: dissolving 5 g of bismuth nitrate into 100 to 500 mL of dilute nitric acid with mass percentage concentration of 10 to 30 percent, adding 80 to 160 mL of glycine with the concentration of 20 to 180 g / L dropwise under stirring, continuously stirring for 10 to 20 minutes after dropwise adding, generating a large amount of precipitate, separating the precipitate, adding the precipitate into ammonia water with the mass percentage concentration of 10 to 20 percent to prepare turbid liquid, transferring the turbid liquid into a hydrothermal reaction kettle of a polytetrafluoroethylene substrate, putting into a drying oven, reacting at 160 to 180 DEGC for 18 to 24 hours, naturally cooling, centrifuging to obtain a solid substance, washing with deionized water and drying to obtain the nitrogen-doped bismuthyl carbonate catalyst. The nitrogen-doped bismuthyl carbonate catalyst obtained through amino acid combination and the hydrothermal reaction of the ammonia water has high dispersibility and a good catalytic effect.

The presently described technology provides a novel class of prodrugs of quetiapine that can be synthesized bu chemically conjugating amino acids to quetiapine. The present technology also provides methods of treating patients, pharmaceutical compositions and methods of synthesizing conjugates of the present technology.

The present invention relates to a method of identifying a candidate compound for modulating bacterial growth. This the method involves providing a β clamp peptide from a bacterial replicase, providing a second peptide that binds to at least one amino acid of SEQ ID NO:9 that is not designated X, wherein the second peptide does not exhibit polymerase activity, and providing a test compound. The β clamp peptide and the second peptide are contacted with the test compound, and the level of binding between the β clamp peptide and the second peptide in the presence of the test compound is determined. The level of binding between the β clamp peptide and the second peptide in the presence of the test compound is then compared to a control that does not contain the test compound. A test compound that alters the level of binding between the β clamp peptide and the second peptide compared to the control is a candidate compound for modulating bacterial growth.